NSG 552 Psychopharmacology Exam 3 Prep Document |
2026/2027 Edition | 250 Verified Questions
NSG 552 Psychopharmacology Exam 3 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100%
Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document features 250 meticulously verified questions covering
all core topics for NSG 552 Psychopharmacology Exam 3. Each question reflects the latest 2026/2027
guidelines, including DSM-5-TR updates and APA practice recommendations. Designed for advanced
practice nursing students, the document provides detailed rationales for correct and incorrect answers,
ensuring thorough understanding of psychopharmacological principles. Ideal for final exam review, it
guarantees A+ performance with pass-guaranteed content.
Key Features:
Antidepressants: SSRIs, SNRIs, MAOIs, and novel agents
Antipsychotics: First- and second-generation, side effect management
Mood Stabilizers: Lithium, anticonvulsants, and emerging therapies
Anxiolytics: Benzodiazepines, buspirone, and non-pharmacological adjuncts
Substance Use Disorders: Pharmacotherapy for alcohol, opioid, and nicotine dependence
Clinical Integration: Case-based questions on dosing, interactions, and monitoring
Updates for 2026:
- Updated to incorporate 2026 DSM-5-TR diagnostic criteria revisions
- Revised guidelines from APA 2026 for schizophrenia and depression treatment
- New questions on emerging therapies (e.g., psychedelics, esketamine)
- Enhanced rationales with current black box warnings and safety alerts
- Added clinical vignettes to reflect real-world prescribing scenarios
Abstract:
This document provides an exhaustive collection of 250 exam-style questions for NSG 552 Psychopharmacology
Exam 3, specifically tailored to the 2026/2027 academic year. The content is meticulously aligned with the latest
evidence-based guidelines from the American Psychiatric Association and the American Society of Clinical
Psychopharmacology. Each question is designed to test knowledge across pharmacokinetics, pharmacodynamics,
and clinical application, with emphasis on nursing implications, patient education, and safety monitoring. The
document includes detailed rationales for each answer choice, systematically explaining why options are correct
or incorrect, thereby reinforcing critical thinking. Developed by psychopharmacology experts, it serves as a
definitive resource for graduate nursing students seeking mastery of advanced psychopharmacology. The inclusion
of distractor analyses ensures that learners can differentiate between subtle clinical nuances, preparing them for
both exam success and clinical practice.
Keywords:
Psychopharmacology, NSG 552, Exam 3, Advanced Practice Nursing, Medication Management, Verified
Questions, 2026/2027, A+ Graded
Answer Format:
Each question is followed by the correct answer and a detailed rationale that explains the underlying mechanism,
clinical indications, and nursing considerations. For incorrect options, targeted explanations clarify why they are
wrong, including common misconceptions. All rationales reference current guidelines and literature, supporting
evidence-based learning.
Compliance Checklist:
Page 1
, All questions reflect current APA and NICE practice guidelines (2026 updates)
Includes generic and brand names to promote prescribing flexibility
Covers lifespan considerations (pediatric, geriatric, pregnancy, lactation)
Addresses black box warnings, contraindications, and drug-drug interactions
Aligns with AACN Essentials for DNP and APRN curriculum standards
Incorporates cultural and genetic factors influencing psychopharmacology
Content Area Overview:
Content Area Questions Key Topics Weight
Antidepressants 1-60 SSRIs, SNRIs, MAOIs, TCAs, atypical 24%
antidepressants, augmentation strategies,
side effect management, discontinuation
syndromes
Antipsychotics 61-110 First-generation (typical) antipsychotics, 20%
second-generation (atypical), clozapine
monitoring, metabolic syndrome, tardive
dyskinesia, long-acting injectables
Mood Stabilizers 111-150 Lithium, valproate, lamotrigine, 16%
carbamazepine, monitoring parameters,
toxicity, bipolar disorder management
Anxiolytics and 151-190 Benzodiazepines, buspirone, z-drugs, 16%
Sedative-Hypnotics ramelteon, melatonin agonists, dependence
and withdrawal, non-pharmacological
treatments
Substance Use Disorders 191-230 Alcohol use disorder (naltrexone, 16%
acamprosate, disulfiram), opioid use
disorder (methadone, buprenorphine,
naltrexone), nicotine dependence
(varenicline, NRT), cannabis and stimulant
use
Special Populations and 231-250 ADHD pharmacotherapy, dementia-related 8%
Emerging Therapies psychosis/agitation, esketamine,
psychedelics, psychopharmacology in
pregnancy/lactation, geriatric considerations
Page 2
,Q1. A patient with major depressive disorder has been on fluoxetine 20 mg daily for 8
weeks with minimal improvement. The prescriber considers augmenting with
bupropion according to current guidelines. What is the most compelling
pharmacological rationale for this combination?
A. Bupropion inhibits serotonin reuptake, complementing fluoxetine's action
B. Bupropion provides additional noradrenergic and dopaminergic activity
C. Bupropion reduces the risk of serotonin syndrome when combined with SSRIs
D. Bupropion prolongs the half-life of fluoxetine, enhancing its efficacy
Correct Answer: B. Bupropion provides additional noradrenergic and dopaminergic
activity
Rationale: Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI), whereas
fluoxetine is an SSRI. The combination targets multiple neurotransmitter systems
(serotonin, norepinephrine, dopamine), which may enhance efficacy in non-responsive
patients. Bupropion does not inhibit serotonin reuptake, does not reduce serotonin
syndrome risk (though it lacks serotonergic activity), and does not significantly alter
fluoxetine pharmacokinetics.
Why Wrong:
A - Bupropion does not inhibit serotonin reuptake; its mechanism is distinct from
SSRIs.
C - Bupropion does not reduce serotonin syndrome risk; the risk remains low due to
its non-serotonergic profile, but this is not a rationale for augmentation.
D - Bupropion does not significantly prolong fluoxetine's half-life; the rationale is
pharmacological synergy, not pharmacokinetic interaction.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 15
(Antidepressants).
Q2. A patient with schizophrenia develops acute dystonia within hours of initiating
haloperidol. Which intervention is most appropriate for immediate symptom relief?
A. Discontinue haloperidol and initiate clozapine
B. Administer intramuscular benztropine
C. Reduce the haloperidol dose by half
D. Start propranolol 20 mg twice daily
Correct Answer: B. Administer intramuscular benztropine
Rationale: Acute dystonia is a common extrapyramidal side effect of first-generation
antipsychotics like haloperidol. It is effectively treated with anticholinergic agents such as
benztropine, which can be given intramuscularly for rapid effect. Discontinuation and
switching to clozapine is not first-line for acute management; dose reduction may help but
does not provide immediate relief. Propranolol is used for akathisia, not dystonia.
Page 3
, Why Wrong:
A - Switching to clozapine may be considered if symptoms persist, but it is not
appropriate for acute dystonia.
C - Dose reduction helps prevent recurrence but does not treat acute symptoms
rapidly.
D - Propranolol is indicated for akathisia, not acute dystonia; anticholinergics are the
treatment of choice.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 17
(Antipsychotics).
Q3. A patient with bipolar I disorder on lithium maintenance therapy presents with a
serum lithium level of 0.8 mEq/L and complains of polyuria over the past month.
Urinalysis shows low specific gravity and absence of glucose. Which condition is most
likely responsible?
A. Poor adherence to lithium resulting in subtherapeutic levels
B. Lithium-induced nephrogenic diabetes insipidus
C. Concurrent diabetes mellitus leading to osmotic diuresis
D. Hypothyroidism causing increased water intake
Correct Answer: B. Lithium-induced nephrogenic diabetes insipidus
Rationale: Lithium is known to cause nephrogenic diabetes insipidus (NDI) even at
therapeutic levels. It impairs the kidney's response to antidiuretic hormone, leading to
polyuria and polydipsia. Urinalysis shows low specific gravity and absence of glucosuria,
ruling out diabetes mellitus. Poor adherence would yield subtherapeutic levels, but the
level is therapeutic. Hypothyroidism may cause fatigue, not polyuria.
Why Wrong:
A - A lithium level of 0.8 mEq/L is within the therapeutic range, indicating good
adherence.
C - Lack of glucosuria and low specific gravity argue against diabetes mellitus as the
cause.
D - Hypothyroidism may cause weight gain and cold intolerance, not typically
polyuria.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 18 (Mood
Stabilizers).
Q4. A patient with generalized anxiety disorder has not responded to a 12-week trial
of sertraline (SSRI) at maximum tolerated dose. Which alternative agent is most
appropriate as monotherapy based on current evidence-based guidelines?
A. Alprazolam 0.5 mg as needed
B. Venlafaxine extended-release 75 mg daily
C. Buspirone 15 mg twice daily
Page 4
2026/2027 Edition | 250 Verified Questions
NSG 552 Psychopharmacology Exam 3 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100%
Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document features 250 meticulously verified questions covering
all core topics for NSG 552 Psychopharmacology Exam 3. Each question reflects the latest 2026/2027
guidelines, including DSM-5-TR updates and APA practice recommendations. Designed for advanced
practice nursing students, the document provides detailed rationales for correct and incorrect answers,
ensuring thorough understanding of psychopharmacological principles. Ideal for final exam review, it
guarantees A+ performance with pass-guaranteed content.
Key Features:
Antidepressants: SSRIs, SNRIs, MAOIs, and novel agents
Antipsychotics: First- and second-generation, side effect management
Mood Stabilizers: Lithium, anticonvulsants, and emerging therapies
Anxiolytics: Benzodiazepines, buspirone, and non-pharmacological adjuncts
Substance Use Disorders: Pharmacotherapy for alcohol, opioid, and nicotine dependence
Clinical Integration: Case-based questions on dosing, interactions, and monitoring
Updates for 2026:
- Updated to incorporate 2026 DSM-5-TR diagnostic criteria revisions
- Revised guidelines from APA 2026 for schizophrenia and depression treatment
- New questions on emerging therapies (e.g., psychedelics, esketamine)
- Enhanced rationales with current black box warnings and safety alerts
- Added clinical vignettes to reflect real-world prescribing scenarios
Abstract:
This document provides an exhaustive collection of 250 exam-style questions for NSG 552 Psychopharmacology
Exam 3, specifically tailored to the 2026/2027 academic year. The content is meticulously aligned with the latest
evidence-based guidelines from the American Psychiatric Association and the American Society of Clinical
Psychopharmacology. Each question is designed to test knowledge across pharmacokinetics, pharmacodynamics,
and clinical application, with emphasis on nursing implications, patient education, and safety monitoring. The
document includes detailed rationales for each answer choice, systematically explaining why options are correct
or incorrect, thereby reinforcing critical thinking. Developed by psychopharmacology experts, it serves as a
definitive resource for graduate nursing students seeking mastery of advanced psychopharmacology. The inclusion
of distractor analyses ensures that learners can differentiate between subtle clinical nuances, preparing them for
both exam success and clinical practice.
Keywords:
Psychopharmacology, NSG 552, Exam 3, Advanced Practice Nursing, Medication Management, Verified
Questions, 2026/2027, A+ Graded
Answer Format:
Each question is followed by the correct answer and a detailed rationale that explains the underlying mechanism,
clinical indications, and nursing considerations. For incorrect options, targeted explanations clarify why they are
wrong, including common misconceptions. All rationales reference current guidelines and literature, supporting
evidence-based learning.
Compliance Checklist:
Page 1
, All questions reflect current APA and NICE practice guidelines (2026 updates)
Includes generic and brand names to promote prescribing flexibility
Covers lifespan considerations (pediatric, geriatric, pregnancy, lactation)
Addresses black box warnings, contraindications, and drug-drug interactions
Aligns with AACN Essentials for DNP and APRN curriculum standards
Incorporates cultural and genetic factors influencing psychopharmacology
Content Area Overview:
Content Area Questions Key Topics Weight
Antidepressants 1-60 SSRIs, SNRIs, MAOIs, TCAs, atypical 24%
antidepressants, augmentation strategies,
side effect management, discontinuation
syndromes
Antipsychotics 61-110 First-generation (typical) antipsychotics, 20%
second-generation (atypical), clozapine
monitoring, metabolic syndrome, tardive
dyskinesia, long-acting injectables
Mood Stabilizers 111-150 Lithium, valproate, lamotrigine, 16%
carbamazepine, monitoring parameters,
toxicity, bipolar disorder management
Anxiolytics and 151-190 Benzodiazepines, buspirone, z-drugs, 16%
Sedative-Hypnotics ramelteon, melatonin agonists, dependence
and withdrawal, non-pharmacological
treatments
Substance Use Disorders 191-230 Alcohol use disorder (naltrexone, 16%
acamprosate, disulfiram), opioid use
disorder (methadone, buprenorphine,
naltrexone), nicotine dependence
(varenicline, NRT), cannabis and stimulant
use
Special Populations and 231-250 ADHD pharmacotherapy, dementia-related 8%
Emerging Therapies psychosis/agitation, esketamine,
psychedelics, psychopharmacology in
pregnancy/lactation, geriatric considerations
Page 2
,Q1. A patient with major depressive disorder has been on fluoxetine 20 mg daily for 8
weeks with minimal improvement. The prescriber considers augmenting with
bupropion according to current guidelines. What is the most compelling
pharmacological rationale for this combination?
A. Bupropion inhibits serotonin reuptake, complementing fluoxetine's action
B. Bupropion provides additional noradrenergic and dopaminergic activity
C. Bupropion reduces the risk of serotonin syndrome when combined with SSRIs
D. Bupropion prolongs the half-life of fluoxetine, enhancing its efficacy
Correct Answer: B. Bupropion provides additional noradrenergic and dopaminergic
activity
Rationale: Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI), whereas
fluoxetine is an SSRI. The combination targets multiple neurotransmitter systems
(serotonin, norepinephrine, dopamine), which may enhance efficacy in non-responsive
patients. Bupropion does not inhibit serotonin reuptake, does not reduce serotonin
syndrome risk (though it lacks serotonergic activity), and does not significantly alter
fluoxetine pharmacokinetics.
Why Wrong:
A - Bupropion does not inhibit serotonin reuptake; its mechanism is distinct from
SSRIs.
C - Bupropion does not reduce serotonin syndrome risk; the risk remains low due to
its non-serotonergic profile, but this is not a rationale for augmentation.
D - Bupropion does not significantly prolong fluoxetine's half-life; the rationale is
pharmacological synergy, not pharmacokinetic interaction.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 15
(Antidepressants).
Q2. A patient with schizophrenia develops acute dystonia within hours of initiating
haloperidol. Which intervention is most appropriate for immediate symptom relief?
A. Discontinue haloperidol and initiate clozapine
B. Administer intramuscular benztropine
C. Reduce the haloperidol dose by half
D. Start propranolol 20 mg twice daily
Correct Answer: B. Administer intramuscular benztropine
Rationale: Acute dystonia is a common extrapyramidal side effect of first-generation
antipsychotics like haloperidol. It is effectively treated with anticholinergic agents such as
benztropine, which can be given intramuscularly for rapid effect. Discontinuation and
switching to clozapine is not first-line for acute management; dose reduction may help but
does not provide immediate relief. Propranolol is used for akathisia, not dystonia.
Page 3
, Why Wrong:
A - Switching to clozapine may be considered if symptoms persist, but it is not
appropriate for acute dystonia.
C - Dose reduction helps prevent recurrence but does not treat acute symptoms
rapidly.
D - Propranolol is indicated for akathisia, not acute dystonia; anticholinergics are the
treatment of choice.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 17
(Antipsychotics).
Q3. A patient with bipolar I disorder on lithium maintenance therapy presents with a
serum lithium level of 0.8 mEq/L and complains of polyuria over the past month.
Urinalysis shows low specific gravity and absence of glucose. Which condition is most
likely responsible?
A. Poor adherence to lithium resulting in subtherapeutic levels
B. Lithium-induced nephrogenic diabetes insipidus
C. Concurrent diabetes mellitus leading to osmotic diuresis
D. Hypothyroidism causing increased water intake
Correct Answer: B. Lithium-induced nephrogenic diabetes insipidus
Rationale: Lithium is known to cause nephrogenic diabetes insipidus (NDI) even at
therapeutic levels. It impairs the kidney's response to antidiuretic hormone, leading to
polyuria and polydipsia. Urinalysis shows low specific gravity and absence of glucosuria,
ruling out diabetes mellitus. Poor adherence would yield subtherapeutic levels, but the
level is therapeutic. Hypothyroidism may cause fatigue, not polyuria.
Why Wrong:
A - A lithium level of 0.8 mEq/L is within the therapeutic range, indicating good
adherence.
C - Lack of glucosuria and low specific gravity argue against diabetes mellitus as the
cause.
D - Hypothyroidism may cause weight gain and cold intolerance, not typically
polyuria.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 18 (Mood
Stabilizers).
Q4. A patient with generalized anxiety disorder has not responded to a 12-week trial
of sertraline (SSRI) at maximum tolerated dose. Which alternative agent is most
appropriate as monotherapy based on current evidence-based guidelines?
A. Alprazolam 0.5 mg as needed
B. Venlafaxine extended-release 75 mg daily
C. Buspirone 15 mg twice daily
Page 4
